Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with invasive breast cancer.
- Your breast cancer is triple-negative (ER-negative, HER2-negative, PgR can be positive or negative).
- Your tumor is PD-L1 positive (tested on a biopsy or surgical sample).
- You have had 0 or 1 prior chemotherapy for cancer that has come back, and you have not had paclitaxel or bevacizumab for that recurrence.
- You received immunotherapy (like pembrolizumab) before or after surgery for breast cancer, and your cancer returned after that treatment.
- You are in good enough health to be up and about (ECOG score 0 or 1), and you do not have untreated brain metastases, a second active cancer, or a history of lung inflammation that needed steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Hear when a new Recurrent Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.